Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4082 - IMRT and temozolomide for grade III glioma: Clinical and prognostic factors

Date

09 Oct 2016

Session

Poster display

Presenters

Trinanjan Basu

Citation

Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367

Authors

T. Basu, T. Kataria, S. Goyal, D. Gupta, A. Abhishek, S.S. Bisht

Author affiliations

  • Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, 122001 - Gurgaon/IN
More

Resources

Abstract 4082

Background

To evaluate grade III gliomas treated in the era of IMRT and concurrent plus adjuvant Temozolomide (TMZ) with early clinical outcome and prognostic factors with quality of life.

Methods

53 patients with anaplastic oligodendroglioma(25), anaplastic astrocytoma (18) and anaplastic oligoastrocytoma(10) treated with IMRT and concurrent (95%) and adjuvant TMZ (90%) were analyzed. 1p19q co-deletion data was available for 13 patients. 80% had KPS at least 90 with 30% seizure at presentation. Postoperative MRI was available in 65% cases and IMRT dose was 60 Gy in 30 fractions. First post treatment imaging was performed at 1 month and then at 3 months and 6 months post IMRT and then every 3 months. EORTC quality of life scale C35 and BN 20 was administered before starting IMRT, at completion and then at each follow up. Kaplan-Meier analysis was used to estimate disease free survival (DFS), overall survival (OS) and analysis was done using SPSS version 18.0

Results

The median follow-up was 25 months with 2 year DFS and OS were 75% and 88%. Patients tolerated treatment well with only 5% symptomatic CNS and 8% symptomatic hematological toxicities. 95% completed concurrent TMZ schedule. At 1st evaluation, 30.4% had complete response, at 3 months 40% and at 6 months 43%. At 6 months only 4 % had progressive disease. Llast follow up 46/53 patients were evaluable with 8 deaths and 55% having stable to complete response. On univariate analysis for DFS, KPS at presentation > 90 (p = 0.001) and response at 6 months (p = 0.02) were significant and for OS KPS at presentation (p = 0.004) alone. Gross total resection, no residual at postoperative MRI, upto 6 cycles of adjuvant TMZ, complete response at 6 months were favorable in terms of both DFS and OS. Histopathological types were not significant for DFS and OS and only 3 patients were 1p19q co-deletion positive. Quality of life scales suggested decline in mood, cognition, fatigue and toilet control initially and improvement beyond 3 months. There were no significant late effects till last follow up.

Conclusions

IIMRT with TMZ among grade III glioma patients resulted in minimum treatment related toxicities and better quality of life with encouraging results. Proper case selection with future molecular prognostic markers will determine most favorable groups.

Clinical trial identification

Legal entity responsible for the study

Medanta The Medicity, Gurgaon

Funding

Medanta The Medicity, Gurgaon

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings